KR102706743B1 - 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도 - Google Patents

인간 il-15에 특이적으로 결합하는 항체 및 이의 용도 Download PDF

Info

Publication number
KR102706743B1
KR102706743B1 KR1020237031493A KR20237031493A KR102706743B1 KR 102706743 B1 KR102706743 B1 KR 102706743B1 KR 1020237031493 A KR1020237031493 A KR 1020237031493A KR 20237031493 A KR20237031493 A KR 20237031493A KR 102706743 B1 KR102706743 B1 KR 102706743B1
Authority
KR
South Korea
Prior art keywords
ser
gly
asn
seq
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237031493A
Other languages
English (en)
Korean (ko)
Other versions
KR20230135691A (ko
Inventor
데이비드 호세 사이먼 레인
메튜 폴라드
앤소니 제랄드 도일
린 도로시 폴톤
애덤 윌리엄 클라크
Original Assignee
세파론 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세파론 엘엘씨 filed Critical 세파론 엘엘씨
Publication of KR20230135691A publication Critical patent/KR20230135691A/ko
Application granted granted Critical
Publication of KR102706743B1 publication Critical patent/KR102706743B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5443IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
KR1020237031493A 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도 Active KR102706743B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
US62/437,143 2016-12-21
PCT/US2017/067917 WO2018119246A1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof
KR1020197019269A KR20190097094A (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019269A Division KR20190097094A (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20230135691A KR20230135691A (ko) 2023-09-25
KR102706743B1 true KR102706743B1 (ko) 2024-09-19

Family

ID=62627610

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237031493A Active KR102706743B1 (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
KR1020197019269A Abandoned KR20190097094A (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197019269A Abandoned KR20190097094A (ko) 2016-12-21 2017-12-21 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도

Country Status (30)

Country Link
US (2) US11267883B2 (enExample)
EP (2) EP4585261A3 (enExample)
JP (2) JP7155126B2 (enExample)
KR (2) KR102706743B1 (enExample)
CN (1) CN110234349B (enExample)
AR (1) AR110414A1 (enExample)
AU (2) AU2017382850B2 (enExample)
BR (1) BR112019012570A8 (enExample)
CA (1) CA3046387A1 (enExample)
CL (1) CL2019001729A1 (enExample)
DK (1) DK3558369T3 (enExample)
EA (1) EA201991514A1 (enExample)
ES (1) ES3026508T3 (enExample)
FI (1) FI3558369T3 (enExample)
HR (1) HRP20250482T1 (enExample)
HU (1) HUE071878T2 (enExample)
IL (1) IL267113B2 (enExample)
LT (1) LT3558369T (enExample)
MA (1) MA47130B1 (enExample)
MD (1) MD3558369T2 (enExample)
MX (2) MX2019007357A (enExample)
PE (1) PE20191497A1 (enExample)
PH (1) PH12019501453A1 (enExample)
PL (1) PL3558369T3 (enExample)
PT (1) PT3558369T (enExample)
RS (1) RS66900B1 (enExample)
SI (1) SI3558369T1 (enExample)
UA (1) UA126284C2 (enExample)
WO (1) WO2018119246A1 (enExample)
ZA (1) ZA201903848B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI707038B (zh) 2013-08-05 2020-10-11 美商扭轉生物科技有限公司 重新合成之基因庫
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
HK1258869A1 (zh) 2015-09-18 2019-11-22 Twist Bioscience Corporation 寡核酸变体文库及其合成
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
AU2017382850B2 (en) 2016-12-21 2024-11-21 Cephalon Llc Antibodies that specifically bind to human IL-15 and uses thereof
US11550939B2 (en) 2017-02-22 2023-01-10 Twist Bioscience Corporation Nucleic acid based data storage using enzymatic bioencryption
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
GB2581620A (en) 2017-09-11 2020-08-26 Twist Bioscience Corp GPCR binding proteins and synthesis thereof
CA3079613A1 (en) 2017-10-20 2019-04-25 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
GB2585506A (en) 2018-01-04 2021-01-13 Twist Bioscience Corp DNA-based digital information storage
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
JP2021530243A (ja) 2018-07-25 2021-11-11 アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. 新規il−21プロドラッグおよびそれを使用する方法
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
EP3902816A4 (en) 2018-12-26 2022-09-14 Twist Bioscience Corporation HIGHLY ACCURATE POLYNUCLEOTIDE DE NOVO SYNTHESIS
AU2020227802A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Glp1受容体の変異体核酸ライブラリ
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
EP4034564A4 (en) 2019-09-23 2023-12-13 Twist Bioscience Corporation VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES
US20210179724A1 (en) * 2019-12-09 2021-06-17 Twist Bioscience Corporation Variant nucleic acid libraries for adenosine receptors
WO2022082201A1 (en) * 2020-10-16 2022-04-21 Genentech, Inc. Anti-cleaved icaspase substrate antibodies and methods of use
WO2022159620A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (en) 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001275A1 (en) * 2014-07-02 2016-01-07 Calypso Biotech Sa Antibodies to il-15

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
WO2003017935A2 (en) 2001-08-23 2003-03-06 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05005921A (es) 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
JP4892335B2 (ja) * 2003-02-26 2012-03-07 ゲンマブ エー/エス インターロイキン15(il−15)に特異的なヒト抗体
AR050293A1 (es) * 2004-08-11 2006-10-11 Moll Tomas Polipeptidos de interleuquina-15 mutante
WO2006090750A1 (ja) 2005-02-28 2006-08-31 Institute For Antibodies Co., Ltd. 抗IgSF4抗体及びその利用
EP2418278A3 (en) * 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SG182144A1 (en) 2007-06-01 2012-07-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
AR078650A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Anticuerpo de union a il-1 beta
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US9127057B2 (en) * 2010-07-20 2015-09-08 Teva Pharmaceuticals Ausralia Pty Ltd Anti-IL-23 heterodimer specific antibodies
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
CN103890006A (zh) 2011-08-23 2014-06-25 罗切格利卡特公司 抗mcsp抗体
KR102096224B1 (ko) * 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
MX2015010350A (es) * 2013-02-26 2015-10-29 Roche Glycart Ag Moleculas de union a antigeno biespecificas que activan la celula t.
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
HUE053097T2 (hu) 2015-03-31 2021-06-28 Medimmune Ltd Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
EP3472202A1 (en) 2016-06-15 2019-04-24 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
AU2017382850B2 (en) 2016-12-21 2024-11-21 Cephalon Llc Antibodies that specifically bind to human IL-15 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001275A1 (en) * 2014-07-02 2016-01-07 Calypso Biotech Sa Antibodies to il-15

Also Published As

Publication number Publication date
MX2019007357A (es) 2019-09-05
PH12019501453A1 (en) 2020-06-15
US20200270339A1 (en) 2020-08-27
WO2018119246A1 (en) 2018-06-28
EP4585261A2 (en) 2025-07-16
PT3558369T (pt) 2025-05-06
AR110414A1 (es) 2019-03-27
KR20190097094A (ko) 2019-08-20
FI3558369T3 (fi) 2025-05-02
CN110234349A (zh) 2019-09-13
PE20191497A1 (es) 2019-10-21
ZA201903848B (en) 2023-02-22
LT3558369T (lt) 2025-07-25
US20220127352A1 (en) 2022-04-28
MX2023014081A (es) 2023-12-06
JP2020501583A (ja) 2020-01-23
EA201991514A1 (ru) 2019-12-30
IL267113B1 (en) 2024-05-01
JP2022176324A (ja) 2022-11-25
HRP20250482T1 (hr) 2025-06-20
US11267883B2 (en) 2022-03-08
AU2017382850B2 (en) 2024-11-21
AU2025201185A1 (en) 2025-03-13
JP7155126B2 (ja) 2022-10-18
EP4585261A3 (en) 2025-08-13
EP3558369A1 (en) 2019-10-30
RS66900B1 (sr) 2025-07-31
MA47130B1 (fr) 2025-05-30
ES3026508T3 (en) 2025-06-11
IL267113B2 (en) 2024-09-01
IL267113A (en) 2019-08-29
MD3558369T2 (ro) 2025-08-31
US12410247B2 (en) 2025-09-09
SI3558369T1 (sl) 2025-06-30
BR112019012570A2 (pt) 2019-11-26
DK3558369T3 (da) 2025-05-19
CA3046387A1 (en) 2018-06-28
EP3558369A4 (en) 2020-09-09
UA126284C2 (uk) 2022-09-14
MA47130A (fr) 2019-10-30
CN110234349B (zh) 2024-03-22
PL3558369T3 (pl) 2025-06-23
KR20230135691A (ko) 2023-09-25
BR112019012570A8 (pt) 2023-01-24
EP3558369B1 (en) 2025-03-26
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
HUE071878T2 (hu) 2025-09-28

Similar Documents

Publication Publication Date Title
KR102706743B1 (ko) 인간 il-15에 특이적으로 결합하는 항체 및 이의 용도
JP6938383B2 (ja) イヌインターロイキン4受容体アルファに対する抗体
US11673950B2 (en) ILT7 binding molecules and methods of using the same
WO2020020281A1 (zh) 抗tigit抗体及其用途
JP2010518873A (ja) アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
CA3065553A1 (en) Il17a antibodies and antagonists for veterinary use
TWI873332B (zh) 抗ox40抗體及其用途
KR20230158526A (ko) Ccr9에 결합하는 치료용 결합 분자
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
JP2020504744A (ja) 枯渇活性を有するヒト化cxcr3抗体およびその使用方法
TWI814094B (zh) 貓抗體變異體
EA040821B1 (ru) Антитела, которые специфически связываются с ил-15, и их применение
BR122024020794A2 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
HK40013673A (en) Antibodies that specifically bind to human il-15 and uses thereof
HK40013673B (en) Antibodies that specifically bind to human il-15 and uses thereof
KR20250057832A (ko) 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230914

Application number text: 1020197019269

Filing date: 20190703

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231211

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240808

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240910

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240910

End annual number: 3

Start annual number: 1

PG1601 Publication of registration